Value of Personalized Medicine Specialty Medicines

Grant D. Lawless, RPh, MD, FACP

Video Categories: Value

Grant Lawless provides an overview of the value of personalized medicine in specialty medicines and primary care settings
July 13, 2021
IWTI-Cohen-Fidler-LoaizaBonilla-01-A-Still

Who Should Be Screened for Tumor Mutations?

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, examine who should be tested for tumor mutations.

January 16, 2019

Impact of Reimbursement for Biomarker Testing on Clinical Practice

Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”